A Retrospective Clinical Study on Cardiovascular Complications from Colorectal Cancer
DOI:
https://doi.org/10.59958/hsf.6733Keywords:
colorectal cancer, cardiovascular complications, retrospective study, risk factors, incidence rateAbstract
Objective: To investigate the incidence and risk factors of cardiovascular complications amongst patients with colorectal cancer (CRC). Methods: A retrospective cohort study was conducted on 2085 patients diagnosed with CRC in two tertiary hospitals in China between 2015 and 2020. The patients' medical records were reviewed to identify cardiovascular complications, including myocardial infarction, heart failure, stroke, hypertension, coronary heart disease, heart failure, and arrhythmia. The incidence rate of cardiovascular complications was calculated, and Cox proportional hazards regression analysis was used to identify risk factors. Results: Of the 2085 CRC patients, 329 (15.8%) experienced cardiovascular complications during the follow-up period, with an incidence rate of 17.4 cases per 1000 person-years. The risk was significantly higher in patients who were older than 60 years (adjusted hazard ratio [HR] 2.04, 95% confidence interval [CI] 1.22–3.41), had a higher level of low-density lipoprotein cholesterol (LDL-C) (adjusted HR 2.32, 95% CI 1.31–4.10), had higher levels of serum C-reactive protein (CRP) (adjusted HR 1.57, 95% CI 1.21–2.04), or who underwent chemotherapy or radiotherapy. CRC patients with cardiovascular complications had significantly higher levels of oxidative stress markers, including malondialdehyde (MDA) (5.8 ± 1.2 μmol/L vs. 3.4 ± 0.9 μmol/L, p < 0.001), lower levels of superoxide dismutase (SOD) (85.2 ± 15.6 U/mg protein vs. 112.5 ± 21.3 U/mg protein, p < 0.001), and lower levels of glutathione peroxidase (GPx) (15.6 ± 3.2 U/mg protein vs. 20.4 ± 4.1 U/mg protein, p < 0.001) compared to those without complications. A progressive increase was observed in the proportion of CRC patients with cardiovascular complications over time, rising from 10% in the first year to 38% by the tenth year of follow-up. Conclusion: Cardiovascular complications pose a high risk in CRC patients, particularly amongst older patients and those with higher levels of LDL-C or CRP. Regular monitoring of cardiovascular function should be considered in the management of patients with CRC.
References
Ichikawa N, Homma S, Funakoshi T, Obuchi K, Ohshima T, Uemura K, et al. The incidence of cardiovascular thrombotic complications after laparoscopic resection in colorectal cancer in Japanese hospitals: A large-scale clinical study. Annals of Gastroenterological Surgery. 2021; 6: 396–404.
Kim H, Park IJ, Han Y, Kwon TW, Cho YP. Cardiovascular morbidities in postoperative colorectal cancer patients. Scientific Reports. 2021; 11: 21359.
Pericleous S, Bhogal RH, Mavroeidis VK. The role of circulating biomarkers in the early detection of recurrent colorectal cancer following resection of liver metastases. Frontiers in Bioscience-Landmark. 2022; 27: 189.
Damit D, Patnaik R, Chaw LL, Lu SK, Telisinghe PU, Lu ZH,et al. KRAS Mutation: Characterization and Its Impact on Survival Outcome of Patients with Metastatic Colorectal Cancer. Frontiers in Bioscience-Landmark. 2022; 27: 213.
Lichtenstern CR, Ngu RK, Shalapour S, Karin M. Immunotherapy, Inflammation and Colorectal Cancer. Cells. 2020; 9: 618.
Yamazaki K, Nagase M, Tamagawa H, Ueda S, Tamura T, Murata K, et al. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2016; 27: 1539–1546.
Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, et al. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial. Nature Medicine. 2023; 29: 2087–2098.
Lonardi S, Rasola C, Lobefaro R, Rossini D, Formica V, Scartozzi M, et al. Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by GONO Foundation. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2023; JCO2300506.
Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2023; 41: 3663–3669.
Bertocchi A, Carloni S, Ravenda PS, Bertalot G, Spadoni I, Lo Cascio A, et al. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. Cancer Cell. 2021; 39: 708–724.e11.
Ricciotti E, FitzGerald GA. Aspirin in the Prevention of Cardiovascular Disease and Cancer. Annual Review of Medicine. 2021; 72: 473–495.
Vallerio P, Sarno L, Stucchi M, Musca F, Casadei F, Maloberti A, et al. Long-Term Effects of Radiotherapy on Arterial Stiffness in Breast Cancer Women. The American Journal of Cardiology. 2016; 118: 771–776.
Totzeck M, Schuler M, Stuschke M, Heusch G, Rassaf T. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. International Journal of Cardiology. 2019; 280: 163–175.
Sung KC, Rhee EJ, Kim H, Park JB, Kim YK, Rosenson RS. Prevalence of low LDL-cholesterol levels and elevated high-sensitivity C-reactive protein levels in apparently healthy Korean adults. Nutrition, Metabolism, and Cardiovascular Diseases: NMCD. 2012; 22: 1061–1066.
Ndrepepa G, Braun S, Tada T, Guerra E, Schunkert H, Laugwitz KL, et al. Comparative prognostic value of low-density lipoprotein cholesterol and C-reactive protein in patients with stable coronary artery disease treated with percutaneous coronary intervention and chronic statin therapy. Cardiovascular Revascularization Medicine: Including Molecular Interventions. 2014; 15: 131–136.
Kawada-Watanabe E, Yamaguchi J, Sekiguchi H, Arashi H, Ogawa H, Hagiwara N. Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial. Journal of Cardiology. 2020; 75: 500–506.
André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status. Current Colorectal Cancer Reports. 2013; 9: 261–269.
Yamada Y, Denda T, Gamoh M, Iwanaga I, Yuki S, Shimodaira H, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018; 29: 624–631.
Shen H, Khan R, Wang X, Li Z, Qu F. Capillary-based chemiluminescence immunoassay for C-reactive protein with portable imaging device. Analytical and Bioanalytical Chemistry. 2018; 410: 7177–7183.
Abedi A, Ghobadi H, Sharghi A, Iranpour S, Fazlzadeh M, Aslani MR. Effect of saffron supplementation on oxidative stress markers (MDA, TAC, TOS, GPx, SOD, and pro-oxidant/antioxidant balance): An updated systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Medicine. 2023; 10: 1071514.
Tejchman K, Sierocka A, Kotfis K, Kotowski M, Dolegowska B, Ostrowski M, et al. Assessment of Oxidative Stress Markers in Hypothermic Preservation of Transplanted Kidneys. Antioxidants (Basel, Switzerland). 2021; 10: 1263.
Wang J, Yang J, Wang C, Zhao Z, Fan Y. Systematic Review and Meta-Analysis of Oxidative Stress and Antioxidant Markers in Oral Lichen Planus. Oxidative Medicine and Cellular Longevity. 2021; 2021: 9914652.
Delrieu L, Touillaud M, Pérol O, Morelle M, Martin A, Friedenreich CM, et al. Impact of Physical Activity on Oxidative Stress Markers in Patients with Metastatic Breast Cancer. Oxidative Medicine and Cellular Longevity. 2021; 2021: 6694594.
Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019; 140: e596–e646.
Aslanger EK, Meyers HP, Smith SW. Time for a new paradigm shift in myocardial infarction. Anatolian Journal of Cardiology. 2021; 25: 156–162.
King M, Kingery J, Casey B. Diagnosis and evaluation of heart failure. American Family Physician. 2012; 85: 1161–1168.
Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJB, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013; 44: 2064–2089.
Alderman MH, Furberg CD, Kostis JB, Laragh JH, Psaty BM, Ruilope LM, et al. Hypertension guidelines: criteria that might make them more clinically useful. American Journal of Hypertension. 2002; 15: 917–923.
de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Human Reproduction Update. 2011; 17: 495–500.
Vukmir RB. Cardiac arrhythmia therapy. The American Journal of Emergency Medicine. 1995; 13: 459–470.
Wu W, Yang J, Li D, Huang Q, Zhao F, Feng X, et al. Competitive Risk Analysis of Prognosis in Patients With Cecum Cancer: A Population-Based Study. Cancer Control: Journal of the Moffitt Cancer Center. 2021; 28: 1073274821989316.
Li WQ, Yang L, Wang SF, Zhang LW, Sheng C, Huang YB. Application of multi-stage competing risk model to survival data. Zhonghua Yu Fang Yi Xue Za Zhi [Chinese Journal of Preventive Medicine]. 2021; 55: 1524–1529. (In Chinese)
Lee SF, Yip PL, Vellayappan BA, Chee CE, Wong LC, Wan EYF, et al. Incident Cardiovascular Diseases Among Survivors of High-Risk Stage II-III Colorectal Cancer: A Cluster-Wide Cohort Study. Journal of the National Comprehensive Cancer Network: JNCCN. 2022; 20: 1125–1133.e10.
Jelic MD, Mandic AD, Maricic SM, Srdjenovic BU. Oxidative stress and its role in cancer. Journal of Cancer Research and Therapeutics. 2021; 17: 22–28.
Lin Y, Jiang M, Chen W, Zhao T, Wei Y. Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2019; 118: 109249.
Songbo M, Lang H, Xinyong C, Bin X, Ping Z, Liang S. Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicology Letters. 2019; 307: 41–48.
Wei R, Zhao Y, Wang J, Yang X, Li S, Wang Y, et al. Tagitinin C induces ferroptosis through PERK-Nrf2-HO-1 signaling pathway in colorectal cancer cells. International Journal of Biological Sciences. 2021; 17: 2703–2717.
Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, et al. Vascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease. Oxidative Medicine and Cellular Longevity. 2019; 2019: 7092151.
Mittal M, Siddiqui MR, Tran K, Reddy SP, Malik AB. Reactive oxygen species in inflammation and tissue injury. Antioxidants & Redox Signaling. 2014; 20: 1126–1167.
Boldig K, Ganguly A, Kadakia M, Rohatgi A. Managing life-threatening 5-fluorouracil cardiotoxicity. BMJ Case Reports. 2022; 15: e251016.
Ben-Yakov M, Mattu A, Brady WJ, Dubbs SB. Prinzmetal angina (Coronary vasospasm) associated with 5-fluorouracil chemotherapy. The American Journal of Emergency Medicine. 2017; 35: 1038.e3–1038.e5.
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nature Reviews. Cardiology. 2020; 17: 474–502.
Qi L, Luo Q, Zhang Y, Jia F, Zhao Y, Wang F. Advances in Toxicological Research of the Anticancer Drug Cisplatin. Chemical Research in Toxicology. 2019; 32: 1469–1486.
Depetris I, Marino D, Bonzano A, Cagnazzo C, Filippi R, Aglietta M, et al. Fluoropyrimidine-induced cardiotoxicity. Critical Reviews in Oncology/hematology. 2018; 124: 1–10.
Thuny F, Naidoo J, Neilan TG. Cardiovascular complications of immune checkpoint inhibitors for cancer. European Heart Journal. 2022; 43: 4458–4468.
Sueur B, Pellerin O, Voron T, Pointet AL, Taieb J, Pernot S. Unresectable liver metastases in colorectal cancer: review of current strategies. Minerva Chirurgica. 2016; 71: 382–397.
Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (London, England). 2013; 27: 787–794.
An Q, Yu T, Cao X, Yang H, Zhao G, Wu G, et al. Comparative analysis of postoperative complications on elderly colorectal cancer patients over 65 years with and without comorbid cardiovascular diseases. Zhonghua Wei Chang Wai Ke Za Zhi = Chinese Journal of Gastrointestinal Surgery. 2016; 19: 1035–1039. (In Chinese)
Hsu HY, Chern YJ, Hsieh CT, Yeh TL, Tsai MC, Wang CC, et al. Increased standardised incidence ratio of cardiovascular diseases among colorectal cancer patients. International Journal of Colorectal Disease. 2022; 37: 887–894.
